【环球网财经综合报道】国家基本药物目录调整工作迎来关键性制度文件。2月11日，国家卫生健康委、国家发展改革委、工业和信息化部、财政部、商务 部、市场监管总局、国家医保局等11部门联合印发《国家基本药物目录管理办法》（简称《办法》），自发布之日起施行。原国家卫生计生委2015年2月13 日印发的《国家基本药物目录管理办法》同时废止。时隔11年，《办法》的发布被业内视为新版国家基本药物目录即将调整的重要信号。 此次发布的《办法》主要从六个方面进行了修订，其中最引人关注的是完善了目录管理机制，明确提出国家基本药物供应使用与分级诊疗、药品集中采购、 支付报销等政策相衔接。在药品遴选方面，《办法》突出了药品临床价值，明确根据疾病谱变化、药品临床应用实践、药品标准变化、药品新上市情况等进 行动态调整。同时，明确了目录制定程序，包括组建专家库、咨询专家组提出遴选意见、评审专家组进行综合评议、征求成员单位意见以及报批发布等五个 关键环节。 《办法》强调，纳入国家基本药物目录的药品，应当是经国家药监局批准，并取得药品注册证书的药品，以及按国家药品标准炮制的中药饮片。除急救用药 外，独家生产品种纳入目录应当经过单独论证。对于含有 ...

Group 1 - The core viewpoint of the news is that Wanbangde (002082) experienced a significant stock price increase due to advancements in innovative drug development, particularly for Alzheimer's disease and ALS treatments [1] - The company's Alzheimer's drug, Shisujianjia controlled-release tablets, completed the enrollment of 100 subjects in a key Phase II/III clinical trial, and the ALS drug received FDA orphan drug designation [1] - Wanbangde's project has been included in the National Science and Technology Major Project, highlighting its technological strength [1] Group 2 - The stock price of Wanbangde increased by 17.00% over the past week, with a trading range fluctuation of 25.00% [2] - Following the stock price surge on February 10, it slightly declined to 18.58 yuan on February 11, with a minor decrease of 0.05% and a trading volume of 5.36 billion yuan [2] - The capital flow indicates a strong short-term interest, with a net inflow of 55.66 million yuan on February 10 and 0.91 million yuan on February 11 [2]

Core Viewpoint - SHP2 inhibitors are emerging as a significant target for cancer treatment, with rapid development in the industry, particularly in China, which is becoming a notable player in the global market [1][6][9]. Industry Overview - SHP2, a protein tyrosine phosphatase, plays a crucial role in regulating various cellular functions, including growth, differentiation, and oncogenic transformation [2][6]. - The global market for SHP2 inhibitors is projected to start existing from 2027, reaching approximately $329 million by 2029, and is expected to grow to $4.821 billion by 2033 [1][7][9]. Market Size - The Chinese SHP2 inhibitor market is anticipated to grow to $206 million by 2029 and reach $784 million by 2033 [9][10]. Industry Chain - The SHP2 inhibitor industry chain includes upstream components such as protein reagents, specific antibodies, small molecule building blocks, testing kits, and experimental models; midstream involves drug research and production; downstream consists of large oncology specialty hospitals and comprehensive hospital oncology departments [11][12]. Development Environment - Recent policies in China have been implemented to encourage the pharmaceutical industry, particularly in the development and production of innovative drugs, including cancer therapies, by shortening clinical application and approval times [13][14]. Competitive Landscape - Major companies in the SHP2 inhibitor space include Innovent Biologics, CanSino Biologics, Junshi Biosciences, and others, with significant progress in developing SHP2 inhibitors, although no drugs have yet been approved for commercialization [15][16]. - Notable companies include: - **QinHao Pharmaceutical**: Focused on developing innovative candidates targeting the RAS signaling pathway, with its lead candidate GH21 in Phase II clinical trials [15][16]. - **Nuocheng Jianhua**: Known for its BTK inhibitor, it is also developing a new SHP2 inhibitor, ICP-189, in collaboration with ArriVent Biopharma [16][17]. Future Outlook - The SHP2 inhibitor sector is one of the hottest areas in pharmaceutical research, with significant advancements in the development of allosteric inhibitors and ongoing clinical trials showing promising results [17][18].

《自然-通讯》发布全文DOI：https://doi.org/10.1038/s41467-026-69225-2 在伴有PIK3CA/AKT1/PTEN通路改变的患者中，研究者评估的确认客观缓解率（confirmed ORR）为 33.3% 在ESR1突变并伴随PIK3CA/AKT1/PTEN通路改变人群中，确认客观缓解率（confirmed ORR）达42.9% 徐兵河院士团队在文章结论中表示，此次Ib研究证实，对于经治的HR+/HER2-晚期乳腺癌患者， LAE002（afuresertib）联合氟维司群治疗方案展现出有前景的疗效和良好的安全性。其疗效在 PIK3CA/AKT1/PTEN通路改变患者中尤为突出。LAE002（afuresertib）良好的安全性特征，以及便捷的 每日一次口服的给药方式，使其成为该患者群体一个颇具吸引力的治疗选择。这些数据有力地支持了 LAE002（afuresertib）在晚期乳腺癌治疗领域的进一步开发和应用。 目前，由徐兵河院士牵头的LAE002（afuresertib）联合氟维司群，针对治疗HR+/HER2-局部晚期或转移 性乳腺癌（LA/mBC）伴随PIK3CA/A ...

Investment Rating - The report maintains a "Recommended" rating for companies involved in the small nucleic acid drug sector targeting obesity [4]. Core Insights - The obesity treatment market is gaining significant attention, with GLP-1 drugs demonstrating efficacy in weight loss, but they also have high rebound rates post-treatment and associated muscle loss. Small nucleic acid drugs offer a different approach by targeting fat metabolism at the genetic level [12][21]. - Arrowhead and Wave Life have shown promising initial results for their small nucleic acid drugs ARO-INHBE and WVE-007, respectively, indicating effective fat reduction without muscle loss [22][38]. - The collaboration between major pharmaceutical companies and small nucleic acid drug developers is intensifying, with significant investments aimed at advancing RNAi therapies for metabolic diseases [49]. Summary by Sections 1. Unmet Needs in Obesity Treatment - The report highlights the unmet demand in obesity treatment, emphasizing that small nucleic acid drugs could provide solutions by directly intervening in fat metabolism [12][16]. 2. Initial Efficacy of Small Nucleic Acid Drugs - Arrowhead's ARO-INHBE demonstrated an average fat reduction of 9.9% and a liver fat reduction of 38.6%, while also increasing lean tissue by 3.6% [22][27]. - Wave Life's WVE-007 showed a 9.4% reduction in visceral fat and a 4.5% reduction in total fat after three months, with a 3.2% increase in lean body mass [38][49]. 3. Investment Recommendations - The report suggests focusing on companies developing small nucleic acid drugs for obesity, including HengRui Medicine, Chengdu XianDao, China Biopharmaceutical, and others [50].

Group 1 - The company, Jingxin Pharmaceutical, announced that it submitted an application for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange on February 11, 2026 [1] - The application materials for this issuance and listing were published on the Hong Kong Stock Exchange website on the same day [1]

Group 1 - The company, Jingxin Pharmaceutical (002020), has submitted an application for the issuance of overseas listed shares (H shares) to the Hong Kong Stock Exchange on February 11, 2026 [1] - The application materials for this issuance and listing have been published on the Hong Kong Stock Exchange website on the same day [1]

Core Viewpoint - The company, Jingxin Pharmaceutical (002020.SZ), has submitted an application for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange on February 11, 2026 [1] Group 1 - The application materials for this issuance and listing have been published on the Hong Kong Stock Exchange website on the same day [1]

Core Viewpoint - The FDA has granted Fast Track Designation (FTD) to Irpagratinib (ABSK-011), a selective FGFR4 inhibitor developed by the company, for the treatment of advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have previously received immune checkpoint inhibitors (ICI) and multi-target kinase inhibitors (mTKI) [1][4]. Group 1: FDA Fast Track Designation - The Fast Track Designation aims to expedite the development and review process of innovative therapies for serious diseases with unmet clinical needs, allowing for earlier and more frequent communication with the FDA [3]. - The designation will accelerate global clinical development and registration processes for Irpagratinib, potentially shortening the time to market [3]. Group 2: Clinical Data and Efficacy - In a Phase I clinical study presented at the 2024 ESMO annual meeting, Irpagratinib demonstrated an objective response rate (ORR) of 46.7% and a median progression-free survival (mPFS) of 5.5 months in HCC patients with FGF19 overexpression who had progressed after ICI and mTKI treatments [4]. - The safety and tolerability profile of Irpagratinib was reported to be favorable [4]. Group 3: Combination Therapy Exploration - The company is also exploring combination therapy with Irpagratinib and Roche's PD-L1 inhibitor Atezolizumab, which has shown an ORR exceeding 50% and mPFS over 7 months in both treatment-naive and previously treated FGF19 overexpressing HCC patients, with no new safety signals observed [4]. - The results suggest a potential synergistic mechanism between FGFR4 inhibitors and ICIs, aligning with accumulating preclinical and translational research evidence [4]. Group 4: Precision Oncology Shift - Irpagratinib represents a significant shift towards precision oncology in the treatment of liver cancer, moving away from relatively non-selective systemic therapies [5]. - The development path of Irpagratinib aligns closely with the global trend towards molecularly driven precision therapies, aiming to establish a new treatment paradigm for patients with FGF19 overexpression [5].

Core Viewpoint - The FDA has granted Fast Track Designation (FTD) to Irpagratinib (ABSK-011), a selective FGFR4 inhibitor developed by the company, for the treatment of advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have previously received immune checkpoint inhibitors (ICI) and multi-targeted kinase inhibitors (mTKI) [1][3][4]. Group 1: FDA Fast Track Designation - The Fast Track Designation aims to expedite the development and review process of innovative therapies for serious diseases with unmet clinical needs, allowing for earlier and more frequent communication with the FDA [3]. - The designation will accelerate global clinical development and registration processes for Irpagratinib, potentially shortening the time to market [3][4]. Group 2: Clinical Data and Efficacy - In a Phase I clinical study presented at the 2024 ESMO annual meeting, Irpagratinib demonstrated an objective response rate (ORR) of 46.7% and a median progression-free survival (mPFS) of 5.5 months in HCC patients with FGF19 overexpression who had progressed after ICI and mTKI treatments [4]. - The safety and tolerability profile of Irpagratinib was reported to be favorable, showing significant advantages over previous treatment data for HCC patients [4]. Group 3: Combination Therapy Exploration - The company is also exploring combination therapy with Irpagratinib and Roche's PD-L1 inhibitor Atezolizumab, which has shown an ORR exceeding 50% and mPFS over 7 months in both treatment-naive and previously treated HCC patients with FGF19 overexpression [4]. - No new safety signals were observed in the combination therapy, suggesting a potential synergistic mechanism between FGFR4 inhibitors and ICIs [4]. Group 4: Precision Oncology Shift - Irpagratinib represents a significant shift towards precision oncology in the treatment of liver cancer, aligning with global trends in molecularly driven precision therapies [5]. - The development of Irpagratinib aims to establish a new treatment paradigm for patients with FGF19 overexpression, promoting a more targeted approach in HCC treatment [5].